ARCT Arcturus Therapeutics Holdings Inc.
Healthcare$7.21+2.56%ClosedMarket Cap: $204.9M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.04
P/S
4.41
EV/EBITDA
-0.11
DCF Value
$-5.45
FCF Yield
-29.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.2%
Operating Margin
-196.7%
Net Margin
-173.5%
ROE
-36.6%
ROA
-32.1%
ROIC
-42.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $610.0K | -7.9% | $-29.8M | $-27.0M | $— | — |
| Q4 null | $3.1M | 100.0% | $-31.3M | $-29.1M | $— | — |
| FY null | $67.2M | 95.5% | $-75.0M | $-65.8M | $— | — |
| Q3 null | $17.2M | 80.5% | $-16.5M | $-13.4M | $— | — |
| Q2 null | $24.5M | 100.0% | $-11.6M | $-9.2M | $— | — |
| Q1 null | $29.4M | 100.0% | $-16.8M | $-14.1M | $— | — |
| Q4 null | $21.0M | 100.0% | $-33.4M | $-30.0M | $— | — |
| FY null | $138.4M | 100.0% | $-95.7M | $-80.9M | $— | — |
| Q3 null | $38.8M | 100.0% | $-10.7M | $-6.9M | $— | — |
| Q2 null | $46.0M | 100.0% | $-21.1M | $-17.2M | $— | — |
| Q1 null | $32.6M | 100.0% | $-30.4M | $-26.8M | $— | — |
| Q4 2023 | $25.1M | 100.0% | $-18.3M | $-11.7M | $-0.32 | — |